Dynavax Technologies Corp. (Nasdaq: DVAX) reported positive results from a Phase 3 clinical trial of its hepatitis B vaccine HEPLISAV-B(TM). Shares of the biopharmaceutical leaped $6.46 to $27.64.
Positive trial results for Dynavax Technologies
January 07, 2016 at 13:56 PM EST
